Mortality and prognostic factors in patients with bullous pemphigoid: a retrospective multicenter Italian study
暂无分享,去创建一个
G. D’Arrigo | L. Atzori | P. Gisondi | C. De Simone | G. Tripepi | C. Tagliati | A. Campanati | G. Genovese | M. Chessa | L. Bigi | C. Feliciani | A. Borghi | R. Balestri | D. Schena | C. Loi | F. Bardazzi | V. Di Lernia | M. Iommi | F. Filippi | G. Rech | G. Rizzetto | C. Lasagni | S. Muratori | A. Pitino | F. Moro | G. Di Zenzo | Mercedes Gori
[1] A. Patrizi,et al. Mortality of patients with bullous pemphigoid in Italy: a retrospective study of a monocentric experience. , 2021, Italian journal of dermatology and venereology.
[2] D. Kivaranovic,et al. Anti‐BP180 autoantibody levels at diagnosis correlate with 1‐year mortality rates in patients with bullous pemphigoid , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.
[3] S. Fisher,et al. Mortality and risk factors among Israeli bullous pemphigoid patients , 2018, Archives of Dermatological Research.
[4] H. Williams,et al. Prospective study in bullous pemphigoid: association of high serum anti‐BP180 IgG levels with increased mortality and reduced Karnofsky score , 2018, The British journal of dermatology.
[5] Y. Won,et al. Mortality and Comorbidity Profiles of Patients with Bullous Pemphigoid in Korea , 2017, Annals of dermatology.
[6] Liang Li,et al. BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid , 2017, Front. Immunol..
[7] D. Zillikens,et al. An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone , 2017, The British journal of dermatology.
[8] S. Fook-Chong,et al. Multimorbidity in bullous pemphigoid: a case–control analysis of bullous pemphigoid patients with age‐ and gender‐matched controls , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.
[9] P. Jagielski,et al. Mortality in bullous pemphigoid and prognostic factors in 1st and 3rd year of follow-up in specialized centre in Poland , 2017, Archives of Dermatological Research.
[10] C. Paul. Rook's Textbook of Dermatology, 9th edn. ChristopherGriffiths, JonathanBarker, TanyaBleiker, RobertChalmers, DanielCreamer, eds. Publisher: Wiley-Blackwell, 2016; 4696 pp. ISBN: 978-1118441190. Price €654.49. , 2017 .
[11] Enno Schmidt,et al. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial , 2017, The Lancet.
[12] F. Antonicelli,et al. Bullous Pemphigoid: A Review of its Diagnosis, Associations and Treatment , 2017, American Journal of Clinical Dermatology.
[13] Michael L. Johnson,et al. Regression coefficient-based scoring system should be used to assign weights to the risk index. , 2016, Journal of clinical epidemiology.
[14] D. Zillikens,et al. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology , 2015, The British journal of dermatology.
[15] J. H. Lee,et al. Mortality of patients with bullous pemphigoid in Korea. , 2014, Journal of the American Academy of Dermatology.
[16] M. Tang,et al. Mortality of bullous pemphigoid in Singapore: risk factors and causes of death in 359 patients seen at the National Skin Centre , 2014, The British journal of dermatology.
[17] S. Rojas-Farreras,et al. Mortality of bullous pemphigoid in the first year after diagnosis: a retrospective study in a Spanish medical centre , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.
[18] D. Zillikens,et al. Pemphigoid diseases , 2013, The Lancet.
[19] L. Naldi,et al. Mortality Rate in Bullous Pemphigoid: A Retrospective Monocentric Cohort Study , 2012, Dermatology.
[20] L. Naldi,et al. Mortality of bullous pemphigoid in Switzerland: a prospective study , 2011, The British journal of dermatology.
[21] P. Middleton,et al. Interventions for bullous pemphigoid. , 2010, The Cochrane database of systematic reviews.
[22] N. Korman,et al. Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States. , 2008, Journal of the American Academy of Dermatology.
[23] A. Ormerod,et al. Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North‐east Scotland , 2005, The British journal of dermatology.
[24] Michelle A. Pipitone,et al. Immunobullous diseases. , 2005, Journal of the American Academy of Dermatology.
[25] J. Roujeau,et al. Prediction of survival for patients with bullous pemphigoid: a prospective study. , 2005, Archives of dermatology.
[26] I. García-Doval,et al. Sepsis associated with dermatologic hospitalization is not the cause of high mortality of bullous pemphigoid in Europe. , 2005, The Journal of investigative dermatology.
[27] J. Fairley,et al. Mortality rate of bullous pemphigoid in a US medical center. , 2004, The Journal of investigative dermatology.
[28] M. Meurer,et al. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. , 2002, Archives of dermatology.
[29] L. Vaillant,et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. , 2002, The New England journal of medicine.
[30] J. Roujeau,et al. High risk of death in elderly patients with extensive bullous pemphigoid. , 1998, Archives of dermatology.
[31] F. Wojnarowska,et al. Lack of predictive factors for the clinical course of bullous pemphigoid. , 1992, Journal of the American Academy of Dermatology.
[32] G. Stüttgen. [On immunopathology of the skin]. , 1967, Der Landarzt.
[33] R. Bergman,et al. Mortality in Patients with Bullous Pemphigoid: A Retrospective Cohort Study, Systematic Review and Meta-analysis. , 2019, Acta dermato-venereologica.
[34] Jun Li,et al. Mortality of bullous pemphigoid in China. , 2013, JAMA dermatology.
[35] J. Savin. Death in bullous pemphigoid. , 1987, Clinics in dermatology.
[36] P. Morel,et al. [Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day. A multicenter randomized study]. , 1984, Annales de dermatologie et de venereologie.